Oculis (NASDAQ:OCS) Hits New 12-Month High – Should You Buy?

Oculis Holding AG (NASDAQ:OCS)’s share price reached a new 52-week high on Thursday . The stock traded as high as $26.89 and last traded at $26.04, with a volume of 384101 shares changing hands. The stock had previously closed at $26.00.

Analyst Ratings Changes

A number of research analysts recently issued reports on OCS shares. Lifesci Capital assumed coverage on Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. HC Wainwright raised their target price on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Bank of America cut their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of Oculis in a research note on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.50.

Oculis Stock Performance

The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $20.75 and a 200-day moving average price of $19.27. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -10.33 and a beta of 0.31.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. On average, analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc increased its position in Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares during the period. Compagnie Lombard Odier SCmA increased its holdings in shares of Oculis by 10.6% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after purchasing an additional 10,300 shares in the last quarter. Syquant Capital Sas acquired a new stake in shares of Oculis in the fourth quarter valued at about $3,849,000. Aventura Private Wealth LLC purchased a new stake in Oculis during the fourth quarter worth about $80,000. Finally, Woodline Partners LP grew its position in Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after buying an additional 33,265 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.